Disclaimer

The following content discusses the Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by the FDA-cleared RenovoCath. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

RenovoRx is evaluating the use of TAMP with gemcitabine as a combination product (known as intra-arterial gemcitabine) for the treatment of locally advanced pancreatic cancer (LAPC), including in the ongoing Phase III TIGeR-PaC trial, under a U.S. Investigational New Drug Application. Ongoing clinical studies continue to evaluate safety and clinical outcomes in patients with LAPC. For RenovoCath’s Indications for Use and safety information, please visit IFU.

Learn more about how hospitals are using the TAMP™ therapy platform with the RenovoCath® device in oncology management, and participant experiences in the Phase III TIGeR-PaC clinical trial.*

Woman Receiving Experimental Treatments For Pancreatic Cancer At UPMC

committedlci_homepage.jpg

70-year old patient, Mrs. Darlene Bossolla, was diagnosed with inoperable pancreatic cancer last year. Now, part of the TIGeR-PaC clinical trial at UPMC with Dr. Paula Novelli, Mrs. Bossola is reporting her levels to be down and she is feeling great and that she believes this new procedure should be available to everyone.

Read the full story on CBS Pittsburgh

* Individual results may vary.

RenovoRx is participating in clinical trials and the FDA has not determined the safety and or efficacy of its clinical drug development program.
View All Clinical News